Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome.

Volume: 125, Issue: 6, Pages: 1336 - 1343
Published: Jun 1, 2010
Abstract
Background null Treatments for Churg-Strauss syndrome (CSS), a rare eosinophilic vasculitis characterized by asthma, sinusitis, peripheral eosinophilia, pulmonary infiltrates, and tissue infiltration, are limited by toxicity or poor efficacy. Levels of IL-5, a cytokine regulating eosinophils, can be increased in patients with CSS. Mepolizumab, a humanized monoclonal anti–IL-5 antibody, decreases steroid requirements in patients with non-CSS...
Paper Details
Title
Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome.
Published Date
Jun 1, 2010
Volume
125
Issue
6
Pages
1336 - 1343
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.